更新于：2024-06-30
Piroxicam
吡罗昔康
更新于：2024-06-30
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (1982-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C15H13N3O4S |
InChIKeyQYSPLQLAKJAUJT-UHFFFAOYSA-N |
CAS号36322-90-4 |
关联
50
项与 吡罗昔康 相关的临床试验Clinical trial of a topical emulgel containing piroxicam-entrapped nanoniosomes in patients with osteoarthritis or rheumatoid arthritis complaining joint pain
Comparative Analysis of Piroxicam and Post-isometric Exercises in Improving Knee Osteoarthritis
Investigation of the effect of mesotherapy with piroxicam in the treatment of tennis elbow in comparison with oral medical therapy in terms of improving pain and function
100 项与 吡罗昔康 相关的临床结果
登录后查看更多信息
100 项与 吡罗昔康 相关的转化医学
登录后查看更多信息
100 项与 吡罗昔康 相关的专利（医药）
登录后查看更多信息
3,096
项与 吡罗昔康 相关的文献（医药）2024-06-01IBRO neuroscience reports
Ferulic acid via attenuation of oxidative stress and neuro-immune response utilizes antinociceptive effect in mouse model of formalin test
Article
作者: Balali-Dehkordi, Shima ; Habibian-Dehkordi, Saeid ; Amini-Khoei, Hossein ; Mohajerian, Rahil
Introduction:
Plenty evidences suggests that neuroinflammation and oxidative stress augmented the neural sensitivity specifying that neuro-immune response is involved in the pathophysiology of pain. Ferulic acid (FA), a natural antioxidant found in various fruits, has various pharmacological properties. The purpose of the current study was to assess the antinociceptive effect of FA in a mouse model of formalin test with focus on its anti-neuroinflammatory and antioxidative stress effects.
Methods:
The injection of FA (40 mg/kg), piroxicam (2 mg/kg), and saline (0.9% NaCl) (1 ml/kg) was done intraperitoneally and after one hour, formalin injected into the plantar surface of the hind paw of mice. Then pain behavior was documented during 60 min. Then mice were euthanized and prefrontal cortex (PFC) samples were taken. Malondialdehyde (MDA) level, antioxidant capacity and expression of inflammatory genes, counting tumor necrosis factor (TNF-) and interleukine 1 (IL-1) evaluated in the PFC.
Results:
exhibited that FA declined the pain behavior following injection of formalin. Besides, FA significantly diminished the MDA level and increased the antioxidant capacity in the PFC. We revealed that FA diminished the expression of TNF-α and IL-1β genes in the PFC.
Conclusion:
We conclude that FA exerted antinociceptive effects in the formalin test in mice, at least partially, by reducing oxidative stress and neuroimmune response in the PFC.
2024-03-01Journal of ethnopharmacology
Aqueous extract of the bark of Uncaria tomentosa, an amazonian medicinal plant, promotes gastroprotection and accelerates gastric healing in rats
Article
作者: Mânica, Aline ; Kunst, Francine Mantelli ; de Queiroz E Silva, Thiago Farias ; Vidal Gutiérrez, Max ; Simomura, Viviane Lazari ; Somensi, Lincon Bordignon ; Miorando, Daniela ; de Oliveira, Beatriz Monteiro Magalhães ; Ansolin, Lucas Damo ; Mota da Silva, Luisa ; Buzatto, Maike Valentin ; Roman Junior, Walter Antônio ; Bohnen, Lilian Caroline ; Venzon, Larissa
ETHNOPHARMACOLOGICAL IMPORTANCE:
Uncaria tomentosa Willd. DC., is used in the Amazonian region of South America, wherein ethnic groups use the plant to treat diseases, including gastric disorders. However, despite its widespread popular use, this species has yet to be assessed for its anti-ulcer effects.
AIM OF THE STUDY:
In this study, we aimed to evaluate the in vivo gastroprotective and gastric healing activities of an aqueous extract of the bark of Uncaria tomentosa (AEUt) and sought to gain an understanding of the pharmacological mechanisms underlying these biological effects.
MATERIALS AND METHODS:
To verify the gastroprotective properties rats were treated with AEUt (30, 60, or 120 mg/kg) prior to inducing gastric ulceration with ethanol or piroxicam. Additionally, the involvement of nitric oxide, non-protein sulfhydryl compounds (NP-SH), α-2 adrenergic receptors, and prostaglandins was investigated. Furthermore, a pylorus ligature model was employed to investigate the antisecretory activity of AEUt. The gastric healing effects of AEUt (60 mg/kg) were examined in rats in which ulceration had been induced with 80% acetic acid, whereas the quality of healing was evaluated in mice with interleukin-induced recurrent ulcers. We also evaluated the in vivo thickness of the gastric wall using ultrasonography. Moreover, the levels of reduced glutathione (GSH) and malondialdehyde (MDA) were evaluated in ulcerated mucosa, and we determined the activities of the enzymes myeloperoxidase (MPO), N-acetyl-β-D-glycosaminidase, superoxide dismutase, catalase, and glutathione S-transferase. In addition, we assessed the effects of AEUt on cell viability and subjected the AEUt to phytochemical analyses.
RESULTS:
Administration of the AEUt (60 or 120 mg/kg) prevented ethanol- and piroxicam-induced ulceration, which was also confirmed histologically. Moreover, we observed that pre-treatment with NEM and indomethacin abolished the gastroprotective effects of AEUt, thereby indicating the involvement of NP-SH and prostaglandins in these protective effects. In addition, we found that the administration of AEUt had no appreciable effects on the volume, acidity, or peptic activity of gastric juice. Furthermore, the AEUt (60 mg/kg) accelerated the gastric healing of acetic acid-induced ulcers by 46.2% and ultrasonographic findings revealed a reduction in the gastric wall thickness in this group. The gastric healing effect of AEUt was also accompanied by a reduction in MPO activity. The AEUt (60 mg/kg) also minimized ulcer recurrence in mice exposed to IL-1β and was associated with the maintenance of GSH levels and a reduction in MDA contents. We deduce that the biological effects of AEUt could be associated with the activities of polyphenols and the alkaloids isomitraphylline and mitraphylline, identified as predominant constituents of the AEUt. Furthermore, we found no evidence to indicate that AEUt would have any cytotoxic effects.
CONCLUSION:
Collectively, our findings provide compelling evidence indicating the therapeutic efficacy of U. tomentosa. Our data indicate that compounds in AEUt confer gastroprotection and that this preventive effect of AEUt was accompanied by gastric healing and a reduction in gastric ulcer recurrence. Moreover, we provide evidence to indicate that the gastroprotective and gastric healing effects involve the antioxidant system and anti-inflammatory responses that contribute to preserving the gastric mucosa.
BMC pharmacology & toxicology
Drug-drug interaction assessment based on a large-scale spontaneous reporting system for hepato- and renal-toxicity, and thrombocytopenia with concomitant low-dose methotrexate and analgesics use
Article
作者: Onda, Kenji ; Honma, Takeshi ; Masuyama, Koichi
Abstract:
Background:
Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) treatment and is highly effective with low-dose intermittent administration. MTX is occasionally used in combination with non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen (APAP)/paracetamol for pain or inflammation control. With MTX treatment, the side effects, such as hepatotoxicity, renal failure, and myelosuppression should be considered. These are also seen with analgesics treatment.
Methods:
We used a large spontaneously reported adverse event database (FAERS [JAPIC AERS]) to analyze whether the reporting of adverse events increased upon MTX and analgesic therapy in patients with RA.
Results:
After identifying RA cases, the crude reporting odds ratios (cRORs) for hepatotoxicity, renal failure, and thrombocytopenia associated with the use of MTX, APAP, or NSAIDs were calculated by disproportionality analysis, which revealed significantly higher cRORs for these events. No analgesics showed consistent positive signals for drug-drug interaction (DDI) with concomitant low-dose MTX analyzed using four algorithms for DDI interaction (the Ω shrinkage measure, additive or multiplicative, and combination risk ratio models). However, in renal failure and thrombocytopenia, loxoprofen (Ω025 = 0.08) and piroxicam (Ω025 = 0.46), and ibuprofen (Ω025 = 0.74) and ketorolac (Ω025 = 3.52), respectively, showed positive signals in the Ω shrinkage measure model, and no consistency was found among adverse events or NSAIDs.
Conclusions:
Studies using spontaneous reporting systems have limitations such as reporting bias or lack of patient background; however, the results of our comprehensive analysis support the results of previous clinical or epidemiological studies. This study also demonstrated the usefulness of FAERS for DDI assessment.
100 项与 吡罗昔康 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 滑囊炎 | 日本 | 2007-02-28 | |
| 肌痛 | 日本 | 1986-09-25 | |
| 肩关节周围炎 | 日本 | 1986-09-25 | |
| 网球肘 | 日本 | 1986-09-25 | |
| 腱鞘炎 | 日本 | 1986-09-25 | |
| 创伤和损伤 | 日本 | 1986-09-25 | |
| 骨关节炎 | 美国 | 1982-04-06 | |
| 类风湿关节炎 | 美国 | 1982-04-06 | |
| 疼痛 | 中国 | 1982-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 860 | (Piroxicam) | 夢網製壓鹽鬱鹹選憲襯(襯艱淵齋構鹹構壓膚蓋) = 窪襯衊顧膚齋鏇鑰衊廠 觸顧糧鏇鹽獵夢艱齋簾 (鑰襯顧願簾網鹽夢窪選, 獵窪範夢鏇齋鏇積鹽衊 ~ 糧鏇顧襯鬱糧顧窪淵壓) 更多 | - | 2024-05-06 | ||
(Placebo) | 夢網製壓鹽鬱鹹選憲襯(襯艱淵齋構鹹構壓膚蓋) = 製糧顧壓齋蓋築鏇構鹹 觸顧糧鏇鹽獵夢艱齋簾 (鑰襯顧願簾網鹽夢窪選, 膚觸襯觸壓齋糧觸網範 ~ 鑰廠襯衊壓醖鑰築餘鹹) 更多 | ||||||
临床4期 | - | 105 | 繭窪壓遞夢壓夢鑰鹽選(鏇遞醖顧淵築窪齋艱範) = 廠衊積繭齋鬱膚襯憲夢 醖獵範繭糧構衊蓋構構 (壓淵築顧鏇鬱蓋獵積壓, 鹽鹹構願遞鹽膚獵窪網 ~ 壓鏇範鑰願網網蓋餘鹽) 更多 | - | 2020-09-16 | ||
临床3期 | 54 | ACTX | 鑰鏇鹽顧遞餘襯選膚夢(鑰鑰選糧膚憲艱淵顧製) = 淵鑰築窪衊艱淵鏇製簾 鏇簾築願廠襯鹹顧鬱範 (築願膚憲網獵繭蓋廠網 ) 更多 | - | 2019-10-01 | ||
N/A | - | - | 膚憲襯蓋憲艱願顧鹹廠(壓範範範淵觸範範壓鑰) = 襯鹽鹹獵願衊簾遞餘廠 鏇鹹糧選觸簾簾鏇齋襯 (鑰鬱網選繭餘夢積糧鬱 ) | - | 2008-06-11 | ||
膚憲襯蓋憲艱願顧鹹廠(壓範範範淵觸範範壓鑰) = 範積淵鑰襯鑰憲夢衊鹹 鏇鹹糧選觸簾簾鏇齋襯 (鑰鬱網選繭餘夢積糧鬱 ) | |||||||
N/A | - | 70 | Tramadol/piroxicam combination | 顧選觸廠蓋廠衊餘鹽製(鏇憲襯廠顧鹽壓顧餘遞) = 18% 繭鏇艱窪鏇製壓選壓襯 (構鏇鹽窪顧蓋顧簾淵糧 ) 更多 | - | 2001-06-13 | |
N/A | - | 醖製範鹽窪簾窪遞夢膚(鑰製艱憲築憲築製網觸) = Fewer adverse reactions were observed with piroxicam 選夢鏇廠膚獵獵鏇窪壓 (繭積蓋鑰餘餘醖鹹獵構 ) 更多 | - | 1983-01-01 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用